Stock acquisition rights conditional on ローツェライフサイエンス achieving operating profit of ¥120 million
First written in FY2018-Q2. 3 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2024: 1 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Other".
- FY2026Disclosure that the ¥120 million operating-profit condition has not been metAnnual report
「Net sales in the life sciences business were ¥1,201 million, up 11.8% year on year, and segment income was ¥13 million, down 89.1%.」
The life science business's operating-profit condition for exercising the stock acquisition rights is ¥120 million in any fiscal year, while segment profit disclosed for FY2026 was ¥13 million. - FY2021RestatedAnnual report
「Only if the Company's subsidiary, ローツェライフサイエンス株式会社, achieves operating profit of ¥120 million at least once in any fiscal year from the fiscal year ending February 2018 through the fiscal year ending February 2027」
The terms of the stock acquisition rights conditional on the life science subsidiary achieving ¥120 million in operating profit continue to apply. - FY2019RestatedAnnual report
「Only if ローツェライフサイエンス株式会社 achieves operating profit of ¥120 million at least once in any fiscal year from the fiscal year ending February 2018 through the fiscal year ending February 2027」
The terms of the stock acquisition rights conditional on the life science subsidiary achieving ¥120 million in operating profit continue to apply. - FY2018RestatedAnnual report
「Only if the Company's consolidated subsidiary, ローツェライフサイエンス株式会社, achieves operating profit of ¥120 million at least once in any fiscal year from the fiscal year ending February 2018 through the fiscal year ending February 2027」
The terms of the stock acquisition rights conditional on the life science subsidiary achieving ¥120 million in operating profit remained in place at fiscal year-end. - FY2018-Q2First statedAnnual report
「The stock acquisition rights allocated to each holder may be exercised during the exercise period specified above only if the Company's subsidiary, ローツェライフサイエンス株式会社, achieves operating profit of ¥120 million at least once in any fiscal year from the fiscal year ending February 2018 through the fiscal year ending February 2027.」
The exercise condition for the stock acquisition rights expressly requires the life science subsidiary to achieve operating profit of ¥120 million in at least one fiscal year from the fiscal year ending February 2018 through the fiscal year ending February 2027.